A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
Abroad (travel likely)RecruitingPHASE1
Conditions
Chronic Inducible Urticaria · Chronic Spontaneous Urticaria
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
ICON Early Phase, San Antonio, Texas, United States
Contact: Principal Investigator (Cassandra Key, MD)
Study leads
Enanta Pharmaceuticals, Inc
Study Director
Enanta Pharmaceuticals, Inc